Treatment of invasive candidiasis in immunocompromised pediatric patients

被引:13
作者
Fisher B.T. [1 ]
Zaoutis T.E. [1 ,2 ]
机构
[1] Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA
[2] Department of Pediatrics, Children's Hospital of Philadelphia, University of Pennsylvania School of Medicine, Philadelphia, PA 19104
基金
美国国家卫生研究院;
关键词
Albaconazole; pharmacodynamics; pharmacokinetics; Amphotericin B; therapeutic use; Azoles; Candidiasis; treatment; Echinocandins;
D O I
10.2165/00148581-200810050-00003
中图分类号
学科分类号
摘要
In the last 3 decades, systemic candidiasis has become increasingly recognized as a major source of morbidity and mortality in immunocompromised pediatric patients. As the number of children receiving chemotherapy and bone marrow transplantations continue to increase, clinicians should expect that invasive infections from Candida spp. will also increase in these vulnerable hosts. Fortunately, in the past 15 years, the evolution of older antifungals coupled with the discovery of new classes of antifungal agents has equipped physicians with reasonable options for treating these otherwise life-threatening infections. This review aims to familiarize the reader with the evolving epidemiology of candidiasis in immunocompromised children as well as discuss therapeutic options from each class of antifungal agents. Mechanisms of action, pharmacokinetics, toxicities, resistance patterns, chemotherapy interactions, and clinical relevance in immunocompromised children are reviewed for polyenes, flucytosine (5-fluorocytosine), azoles, and echinocandins. © 2008 Adis Data Information BV. All rights reserved.
引用
收藏
页码:281 / 298
页数:17
相关论文
共 174 条
  • [1] Viscoli C., Girmenia C., Marinus A., Et al., Candidemia in cancer patients: A prospective, multicenter surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC), Clin Infect Dis, 28, 5, pp. 1071-1079, (1999)
  • [2] Beck-Sague C., Jarvis W.R., Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National Nosocomial Infections Surveillance System, J Infect Dis, 167, 5, pp. 1247-1251, (1993)
  • [3] Muller F.M., Groll A.H., Walsh T.J., Current approaches to diagnosis and treatment of fungal infections in children infected with human immuno deficiency virus, Eur J Pediatr, 158, 3, pp. 187-199, (1999)
  • [4] Bodey G.P., The emergence of fungi as major hospital pathogens, J Hosp Infect, 11, SUPPL. A, pp. 411-426, (1988)
  • [5] Fisher M.A., Talbot G.H., Maislin G., Et al., Risk factors for amphotericin B-associated nephrotoxicity, Am J Med, 87, 5, pp. 547-552, (1989)
  • [6] Bodey G.P., Fungal infections complicating acute leukemia, J Chronic Dis, 19, 6, pp. 667-687, (1966)
  • [7] Gruhn J.G., Sanson J., Mycotic infections in leukemic patients at autopsy, Cancer, 16, pp. 61-73, (1963)
  • [8] Casazza A.R., Duvall C.P., Carbone P.P., Infection in lymphoma: Histology, treatment, and duration in relation to incidence and survival, JAMA, 197, 9, pp. 710-716, (1966)
  • [9] Singer C., Kaplan M.H., Armstrong D., Bacteremia and fungemia complicating neoplastic disease: A study of 364 cases, Am J Med, 62, 5, pp. 731-742, (1977)
  • [10] Myerowitz R.L., Pazin G.J., Allen C.M., Disseminated candidiasis: Changes in incidence, underlying diseases, and pathology, Am J Clin Pathol, 68, 1, pp. 29-38, (1977)